ADMS News and Press, Adamas Pharmaceuticals Inc.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to be $90M-$95M, up from prior guidance of $70M-$90M. Net produc...

NEW YORK, NY / ACCESSWIRE / November 1, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) concerning potential violations of the federal securities laws and/or breaches of fiducia...

Adamas Pharmaceuticals announced that Supernus Pharmaceuticals has struck a deal to buy ADMS at $8.10 per share with CVR kickers. I believe this is a perfect time for both companies. Supernus' leading product, Trokendi, is moving closer to its patent expiration in 2023. GOCOVRI might ...

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciar...

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...

Potential deal in the works Aspen Technology materializes. Two deals with Contingent Value Rights announced last week. Navios Maritime Partners completed the acquisition of Navios Maritime Acquisition Corporation. For further details see: Merger Arbitrage Mondays: Emerso...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 wrapped up its best week since July, closing at its highest level in a month, as a series of upside earnings reports from Wal...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...

Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...

Gainers: Protagonist (NASDAQ:PTGX) +86%. Adamas (NASDAQ:ADMS) +75%. Flexion (NASDAQ:FLXN) +63%. Progenity (NASDAQ:PROG) +35%. Gaotu Techedu (NYSE:GOTU) +23%. U.S. Well Services (NASDAQ:USWS) +22%. Blue Apron (NYSE:APRN) +19%. EZFill (NASDAQ:EZFL) +18%. Ocular (NASDAQ:OCUL) +17%. Willamette Va...